BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li MY, Deng H, Zhao JM, Dai D, Tan XY. Peroxisome proliferator-activated receptor gamma ligands inhibit cell growth and induce apoptosis in human liver cancer BEL-7402 cells. World J Gastroenterol 2003; 9(8): 1683-1688 [PMID: 12918101 DOI: 10.3748/wjg.v9.i8.1683] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 El-hela AA, Bakr MSA, Hegazy MM, Dahab MA, Elmaaty AA, Ibrahim AE, El Deeb S, Abbass HS. Phytochemical Characterization of Pterocephalus frutescens with In-Silico Evaluation as Chemotherapeutic Medicine and Oral Pharmacokinetics Prediction Study. Sci Pharm 2023;91:7. [DOI: 10.3390/scipharm91010007] [Reference Citation Analysis]
2 Katoch S, Sharma V, Patial V. Peroxisome proliferator-activated receptor gamma as a therapeutic target for hepatocellular carcinoma: Experimental and clinical scenarios. World J Gastroenterol 2022; 28(28): 3535-3554 [DOI: 10.3748/wjg.v28.i28.3535] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 He Y, Li H, He Y, Lu C, Zhu P, Li M, Duan J, Fang Z. Troglitazone inhibits hepatic oval cell proliferation by inducing cell cycle arrest through Hippo/YAP pathway regulation. Dig Liver Dis 2022;54:791-9. [PMID: 34531129 DOI: 10.1016/j.dld.2021.08.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Bansod S, Saifi MA, Godugu C. Molecular updates on berberine in liver diseases: Bench to bedside. Phytother Res 2021. [PMID: 34056769 DOI: 10.1002/ptr.7181] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
5 Wu L, Guo C, Wu J. Therapeutic potential of PPARγ natural agonists in liver diseases. J Cell Mol Med 2020;24:2736-48. [PMID: 32031298 DOI: 10.1111/jcmm.15028] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 10.3] [Reference Citation Analysis]
6 Ahmad MM, Rezk NA, Fawzy A, Sabry M. Protective effects of curcumin and silymarin against paracetamol induced hepatotoxicity in adult male albino rats. Gene 2019;712:143966. [PMID: 31279711 DOI: 10.1016/j.gene.2019.143966] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
7 Zheng B, Zhu YJ, Wang HY, Chen L. Gender disparity in hepatocellular carcinoma (HCC): multiple underlying mechanisms. Sci China Life Sci. 2017;60:575-584. [PMID: 28547581 DOI: 10.1007/s11427-016-9043-9] [Cited by in Crossref: 44] [Cited by in F6Publishing: 52] [Article Influence: 7.3] [Reference Citation Analysis]
8 Chiu M, McBeth L, Sindhwani P, Hinds TD. Deciphering the Roles of Thiazolidinediones and PPARγ in Bladder Cancer. PPAR Res 2017;2017:4810672. [PMID: 28348577 DOI: 10.1155/2017/4810672] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
9 Chen K, Dai W, Wang F, Xia Y, Li J, Li S, Liu T, Zhang R, Wang J, Lu W, Zhou Y, Yin Q, Zheng Y, Abudumijiti H, Chen R, Lu J, Zhou Y, Guo C. Inhibitive effects of 15-deoxy-Δ(12),(14)-prostaglandin J2 on hepatoma-cell proliferation through reactive oxygen species-mediated apoptosis. Onco Targets Ther 2015;8:3585-93. [PMID: 26664142 DOI: 10.2147/OTT.S92832] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
10 Yu H, Liu Y, Pan W, Shen S, Das UN. Polyunsaturated fatty acids augment tumoricidal action of 5-fluorouracil on gastric cancer cells by their action on vascular endothelial growth factor, tumor necrosis factor-α and lipid metabolism related factors. Arch Med Sci 2015;11:282-91. [PMID: 25995742 DOI: 10.5114/aoms.2015.50962] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
11 Malaguarnera R, Belfiore A. The insulin receptor: a new target for cancer therapy. Front Endocrinol (Lausanne). 2011;2:93. [PMID: 22654833 DOI: 10.3389/fendo.2011.00093] [Cited by in Crossref: 53] [Cited by in F6Publishing: 58] [Article Influence: 4.4] [Reference Citation Analysis]
12 Borbath I, Horsmans Y. The Role of PPARgamma in Hepatocellular Carcinoma. PPAR Res 2008;2008:209520. [PMID: 18509497 DOI: 10.1155/2008/209520] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
13 Rogue A, Spire C, Brun M, Claude N, Guillouzo A. Gene Expression Changes Induced by PPAR Gamma Agonists in Animal and Human Liver. PPAR Res 2010;2010:325183. [PMID: 20981297 DOI: 10.1155/2010/325183] [Cited by in Crossref: 80] [Cited by in F6Publishing: 85] [Article Influence: 6.2] [Reference Citation Analysis]
14 Prakash J, Bansal R, Post E, de Jager-Krikken A, Lub-de Hooge MN, Poelstra K. Albumin-binding and tumor vasculature determine the antitumor effect of 15-deoxy-Delta-(12,14)-prostaglandin-J(2) in vivo. Neoplasia 2009;11:1348-58. [PMID: 20019843 DOI: 10.1593/neo.91188] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
15 Belfiore A, Genua M, Malaguarnera R. PPAR-γ agonists and their effects on IGF-I receptor signaling: Implications for cancer. PPAR Res 2009;2009:830501. [PMID: 19609453 DOI: 10.1155/2009/830501] [Cited by in Crossref: 65] [Cited by in F6Publishing: 75] [Article Influence: 4.6] [Reference Citation Analysis]
16 Wu X, Chen W, Zhang S. Peroxisome proliferator-activated receptor γ expression correlates with tumor angiogenesis in human hepatocellular carcinoma. Chin -Ger J Clin Oncol 2008;7:266-271. [DOI: 10.1007/s10330-008-0022-2] [Reference Citation Analysis]
17 Bugianesi E. Non-alcoholic steatohepatitis and cancer. Clin Liver Dis 2007;11:191-207, x-xi. [PMID: 17544979 DOI: 10.1016/j.cld.2007.02.006] [Cited by in Crossref: 175] [Cited by in F6Publishing: 182] [Article Influence: 10.9] [Reference Citation Analysis]
18 Ming M, Yu JP, Meng XZ, Zhou YH, Yu HG, Luo HS. Effect of ligand troglitazone on peroxisome proliferator-activated receptor γ expression and cellular growth in human colon cancer cells. World J Gastroenterol 2006; 12(45): 7263-7270 [PMID: 17143939 DOI: 10.3748/wjg.v12.i45.7263] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
19 Kim HJ, Woo IS, Kang ES, Eun SY, Kim GH, Ham SA, Kim HJ, Lee JH, Chang KC, Kim JH, Lee HT, Seo HG. Phorbol ester potentiates the growth inhibitory effects of troglitazone via up-regulation of PPARgamma in A549 cells. Biochem Biophys Res Commun 2006;349:660-7. [PMID: 16945329 DOI: 10.1016/j.bbrc.2006.08.085] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
20 Aiello A, Pandini G, Frasca F, Conte E, Murabito A, Sacco A, Genua M, Vigneri R, Belfiore A. Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells. Endocrinology 2006;147:4463-75. [PMID: 16777971 DOI: 10.1210/en.2005-1610] [Cited by in Crossref: 70] [Cited by in F6Publishing: 77] [Article Influence: 4.1] [Reference Citation Analysis]
21 Campbell SE, Stone WL, Lee S, Whaley S, Yang H, Qui M, Goforth P, Sherman D, McHaffie D, Krishnan K. Comparative effects of RRR-alpha- and RRR-gamma-tocopherol on proliferation and apoptosis in human colon cancer cell lines. BMC Cancer. 2006;6:13. [PMID: 16417629 DOI: 10.1186/1471-2407-6-13] [Cited by in Crossref: 68] [Cited by in F6Publishing: 75] [Article Influence: 4.0] [Reference Citation Analysis]
22 Shao YY, Wang L, Hicks DG, Tarr S, Ballock RT. Expression and activation of peroxisome proliferator-activated receptors in growth plate chondrocytes. J Orthop Res 2005;23:1139-45. [PMID: 15878253 DOI: 10.1016/j.orthres.2005.02.011] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.2] [Reference Citation Analysis]
23 Hofseth LJ, Ying L. Identifying and defusing weapons of mass inflammation in carcinogenesis. Biochim Biophys Acta 2006;1765:74-84. [PMID: 16169156 DOI: 10.1016/j.bbcan.2005.08.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 34] [Article Influence: 1.0] [Reference Citation Analysis]
24 Bonne C. [PPAR gamma: a novel pharmacological target against retinal and choroidal neovascularization]. J Fr Ophtalmol 2005;28:326-30. [PMID: 15883500 DOI: 10.1016/s0181-5512(05)81062-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
25 Knight B, Yeap BB, Yeoh GC, Olynyk JK. Inhibition of adult liver progenitor (oval) cell growth and viability by an agonist of the peroxisome proliferator activated receptor (PPAR) family member gamma, but not alpha or delta. Carcinogenesis 2005;26:1782-92. [PMID: 15917308 DOI: 10.1093/carcin/bgi138] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 1.6] [Reference Citation Analysis]
26 Zhao CY, Jiang LL, Li L, Deng ZJ, Liang BL, Li JM. Peroxisome proliferator activated receptor-γ in pathogenesis of experimental fatty liver disease. World J Gastroenterol 2004; 10(9): 1329-1332 [PMID: 15112352 DOI: 10.3748/wjg.v10.i9.1329] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.0] [Reference Citation Analysis]
27 Jia G, Gu YQ, Chen KT, Lu YY, Yan L, Wang JL, Su YP, Wu JCG. Protective role of metallothionein (I/II) against pathological damage and apoptosis induced by dimethylarsinic acid. World J Gastroenterol 2004; 10(1): 91-95 [PMID: 14695776 DOI: 10.3748/wjg.v10.i1.91] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]